US 9,808,470 B2
Estrogenic components for use in the treatment of neurological disorders
Jean-Michel Foidart, Liege (BE); Ekaterine Tskitishvili, Liege (BE); and Renaud Viellevoye, Cerexhe-Heuseux (BE)
Assigned to UNIVERSITE DE LIEGE, Angleur (BE)
Filed by UNIVERSITE DE LIEGE, Angleur (BE)
Filed on Dec. 9, 2015, as Appl. No. 14/963,676.
Application 14/963,676 is a continuation in part of application No. 14/395,465, granted, now 9,238,035, previously published as PCT/EP2013/057279, filed on Apr. 8, 2013.
Claims priority of application No. 12164741 (EP), filed on Apr. 19, 2012.
Prior Publication US 2016/0101116 A1, Apr. 14, 2016
Int. Cl. A61K 31/57 (2006.01); A61K 31/565 (2006.01)
CPC A61K 31/565 (2013.01) [A61K 31/57 (2013.01)] 15 Claims
1. A method of treatment of a newborn subject that has suffered a diffuse white matter injury comprising administering to the subject an amount of an estrogenic component effective for said treatment, said estrogenic component being selected from the group consisting of:
an estrogenic substance of formula (I):

OG Complex Work Unit Drawing
wherein R1, R2, R3, R4 each independently are a hydrogen atom, a hydroxyl group, or an alkoxy group with 1-5 carbon atoms; wherein each of R5, R6, R7 is a hydroxyl group; and wherein no more than 3 of R1, R2, R3, R4 are hydrogen atoms;
a precursor of the estrogenic substance(s), wherein the precursors are derivatives of the estrogenic substance(s) wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranyl; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue; and
a mixture of one or more of the estrogenic substance(s) and/or the precursor(s).